FCA
VRTX icon

Fortis Capital Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Fortis Capital Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$884K Sell
1,980
-124
-6% -$57.8K 0.12% 157
2025
Q4 		$954K Buy
2,104
+27
+1% +$11.6K 0.14% 130
2025
Q3 		$813K Buy
2,077
+342
+20% +$143K 0.13% 136
2025
Q2 		$772K Sell
1,735
-19
-1% -$8.76K 0.14% 118
2025
Q1 		$850K Buy
+1,754
New +$817K 0.17% 103

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fortis Capital Advisors's VRTX Position: Q1 2026 in Review

Fortis Capital Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 5.9% in Q1 2026, selling an estimated $57.8K and leaving 1,980 shares worth $884K. The position accounts for 0.12% of the portfolio, ranked #157.

Fortis Capital Advisors first reported a position in VRTX in Q1 2025 and has held it in 5 quarters since. The position peaked at $954K in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Fortis Capital Advisors held 1,980 shares of Vertex Pharmaceuticals worth $884K as of Q1 2026.
  • Fortis Capital Advisors sold 124 Vertex Pharmaceuticals shares in Q1 2026, an estimated $57.8K.
  • Vertex Pharmaceuticals made up 0.12% of Fortis Capital Advisors's portfolio in Q1 2026, its #157 holding.
  • Fortis Capital Advisors first reported a position in Vertex Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • Fortis Capital Advisors's Vertex Pharmaceuticals position peaked at $954K in Q4 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Fortis Capital Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.